Drugs / CC-8490
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00074243 | Dec 2003 → ? | central nervous system neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00074646 | Dec 2003 → Jun 2005 | glioblastoma | Celgene Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-8490 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00074243 ↗ |
| Route | Oral | “Patients receive oral CC-8490 once daily on days 1 and 3-28 (course 1 only).” NCT00074243 ↗ |